NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 8, 2016--
Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH),
parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global
leader in the development, manufacture and commercialization of
innovative diagnostic imaging agents and products, today announced that
Dr. Patrick O’Neill has retired from his role on its Board of Directors.
He was appointed as a Director in 2008. Additionally, the Company
announced the appointments of Derace Schaffer, M.D., and Frederick
Robertson, M.D., as independent members of its Board of Directors,
effective immediately. The Company's Board of Directors now consists of
eight members, including five independent directors.
“On behalf of the Board of Directors, we thank Pat for his long and
distinguished service to the Company,” said Mary Anne Heino, President
and Chief Executive Officer. “Pat has been a member of the Board since
2008, and we are grateful for his guidance, insights and many
contributions over the past eight years. With Pat’s retirement, we are
appointing two new Directors to our Board.”
Ms. Heino continued, “We welcome Derace and Fred to the Board, both of
whom bring a proven track record of building shareholder value. We
believe that Lantheus will benefit from having two physicians serve on
our Board, bringing the patient and provider perspective into the
boardroom. As we continue to focus on moving our next generation and
pipeline programs forward and pursuing business development
opportunities to further strengthen and grow the Company, each will be
an extremely valuable resource to the Company.”
Dr. Schaffer, who will serve as a member of the Compensation Committee
of the Board, is the founder and Chief Executive Officer of The Lan
Group, a venture capital firm specializing in healthcare and high
technology investments. He has also been a Clinical Professor of
Radiology at both the University of Rochester Medical College as well as
the Weill Cornell Medical College, and he currently serves as a Director
of PharmAthene, Inc. and as the Chairman of its Governance and
Nominating Committee and a member of its Audit and Compensation
Committees. Additionally, he serves as a member of the Board of
Directors of private companies Innovolt, Inc., Medical Tracking
Solutions, Inc. and Partners Imaging. Previously, Dr. Schaffer served as
Vice Chairman and Chief Executive Officer of Healthcare Acquisition
Corp. and as Chairman of several healthcare companies, including
Radiologix, Inc., of which he was the founder. Prior to that, he served
as Chief Executive Officer and Chairman of Ide Imaging Group, P.C. and
held the role of Director on many healthcare Boards, including several
health systems, and has been a founder of more than two dozen companies,
both public and private, over the past 30 years.
Dr. Schaffer received his postgraduate radiology training at Harvard
Medical School and Massachusetts General Hospital, where he served as
Chief Resident, and is a member of the Alpha Omega Alpha Honor Medical
Society.
Dr. Robertson, who will serve as a member of the Audit Committee, has
been a Venture Partner at Baird Capital since 2011 and has also served
as an Assistant Professor of Anesthesiology at the University of
Wisconsin School of Medicine and Public Health since 2012. Previously,
Dr. Robertson held the role of Chief Executive Officer and Director of
TomoTherapy Inc. before that company was acquired in 2011. Prior to
joining TomoTherapy, Dr. Robertson served in a variety of roles in the
medical field, including President and Chief Executive Officer of GE
Marquette Medical Systems and later as Chief Clinical Officer of GE
Medical Systems as well as management positions with Marquette Medical
Systems, including President and Chief Executive Officer. He serves on
the Boards of the University of Wisconsin Foundation, the Morgridge
Institute for Research, Alpha Source, Inc. and Zurex Pharma, Inc.
Dr. Robertson received his MBA from San Diego State University and
earned his M.D. from University of Wisconsin Medical School.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical
Imaging, Inc. (“LMI”), which is a global leader in the development,
manufacture and commercialization of innovative diagnostic imaging
agents and products. LMI provides a broad portfolio of products, which
are primarily used for the diagnosis of cardiovascular diseases. LMI’s
key products include the echocardiography contrast agent DEFINITY®
Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. Lantheus
is headquartered in North Billerica, Massachusetts with offices in
Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160308006660/en/
Source: Lantheus Holdings, Inc.
Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508